Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 15/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinaprilat SCHEMBL7392611 | 1.00 | ACE (1.00) | ACEABCB11PDE3A | |
| Quinaprilat SCHEMBL11306348 | 1.00 | ACE (1.00) | ACEABCB11PDE3A | |
| Quinaprilat SCHEMBL11286565 | 1.00 | ACE (1.00) | ACEABCB11PDE3A | |
| Quinaprilat SCHEMBL11286571 | 1.00 | ACE (1.00) | ACEABCB11PDE3A | |
| Quinaprilat SCHEMBL7421419 | 1.00 | ACE (1.00) | ACEABCB11PDE3A | |
| Quinaprilat SCHEMBL113237 | 1.00 | ACE (1.00) | ACEABCB11PDE3A | |
| Quinaprilat SCHEMBL6438000 | 1.00 | ACE (1.00) | ACEABCB11PDE3A | |
| Quinaprilat SCHEMBL9253792 | 1.00 | ACE (1.00) | ACEABCB11PDE3A | |
| Quinaprilat SCHEMBL27697059 | 0.99 | ACE (0.98) | ACEABCB11PDE3A | |
| Quinaprilat SCHEMBL27717008 | 0.99 | ACE (0.98) | ACEABCB11PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3474836-B1 | SALBUTAMOL-CONTAINING OPHTHALMIC MEDICAMENT | REKIK RAOUF (TN) | 2024-01-17 | — | — | EP | claimed |
| US-11484513-B2 | Salbutamol-containing ophthalmic medicament | REKIK RAOUF (TN) | 2022-11-01 | — | — | US | claimed |
| EP-3659585-B1 | COMPOSITION FOR DELIVERING PHYSIOLOGICALLY ACTIVE INGREDIENTS INTO BLOOD VESSEL | LEMONEX INC (KR) | 2025-06-25 | — | — | EP | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-20250032414-A1 | PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER | LEMONEX INC. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-12138346-B2 | Physiologically active substance carrier | LEMONEX INC. (KR) | 2024-11-12 | — | — | US | disclosed |
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240041771-A1 | PHYSIOLOGICALLY ACTIVE SUBSTANCE CARRIER | LEMONEX INC. (KR) | 2024-02-08 | — | — | US | disclosed |
| EP-3474836-B1 | SALBUTAMOL-CONTAINING OPHTHALMIC MEDICAMENT | REKIK RAOUF (TN) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023224097-A1 | MEMBRANE-FORMING COMPOSITION, MEMBRANE-LIKE COMPOSITION, AND USE OF SAME | 東和薬品株式会社 | 2023-11-23 | — | — | WO | disclosed |
| US-11793757-B2 | Physiologically active substance carrier | LEMONEX INC. (KR) | 2023-10-24 | — | — | US | disclosed |
| EP-3790534-B1 | NANOPARTICLE COMPRISING A BIO-RESORBABLE POLYESTER, A HYDROPHILIC POLYMER AND AN ACYLATED HUMAN LACTOFERRIN-DERIVED PEPTIDE | EVONIK OPERATIONS GMBH (DE) | 2023-08-30 | — | — | EP | disclosed |
| CN-111132666-B | Composition for delivering physiologically active ingredients to blood vessels | 雷莫内克斯生物制药有限公司 | 2022-11-04 | — | — | CN | disclosed |
| US-11484513-B2 | Salbutamol-containing ophthalmic medicament | REKIK RAOUF (TN) | 2022-11-01 | — | — | US | disclosed |
| CN-112043835-B | Bioreversible introducing group for nitrogen and hydroxyl-containing drugs | 韩捷 | 2022-10-21 | — | — | CN | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | ACE 2452/4885ABCB11 4014/4885PDE3A 3744/4885 |
| US-11484513-B2 | Salbutamol-containing ophthalmic medicament | ADRB3, ADRB2, ADRB1 | ACE 667/4885ABCB11 2533/4885PDE3A 188/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | ACE 2452/4885ABCB11 4014/4885PDE3A 3744/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | ACE 1907/4885ABCB11 4350/4885PDE3A 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.